Copy Number Variation in Inflammatory Breast Cancer.
EGFR
chromosome 7p11
copy number alterations
copy number variation
inflammatory breast cancer
multi-omics
subtype
triple-negative
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
04 04 2023
04 04 2023
Historique:
received:
11
02
2023
revised:
29
03
2023
accepted:
31
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Identification of a unique genomic biomarker in de novo inflammatory breast cancer (IBC) may provide an insight into the biology of this aggressive disease. The goal of our study was to elucidate biomarkers associated with IBC. We examined breast biopsies collected from Dana-Farber Cancer Institute patients with IBC prior to initiating preoperative systemic treatment (30 samples were examined, of which 14 were eligible). Patients without available biopsies (
Identifiants
pubmed: 37048158
pii: cells12071086
doi: 10.3390/cells12071086
pmc: PMC10093603
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Natl Cancer Inst. 2012 Jan 18;104(2):87-8
pubmed: 22215853
PLoS One. 2017 Feb 2;12(2):e0170181
pubmed: 28152060
Springerplus. 2013 Oct 01;2:497
pubmed: 24102046
Breast Cancer Res Treat. 2020 Apr;180(2):385-395
pubmed: 32043194
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33007869
Breast Cancer Res Treat. 2015 Jul;152(2):417
pubmed: 26092296
Breast Cancer Res Treat. 2022 Apr;192(2):245-247
pubmed: 35133550
J Clin Oncol. 2014 Sep 1;32(25):e88-91
pubmed: 24516025
JAMA Oncol. 2018 Sep 1;4(9):1207-1213
pubmed: 29879283
Springerplus. 2013 Aug 28;2:409
pubmed: 24156086
Breast Cancer Res Treat. 2013 Apr;138(3):761-72
pubmed: 23568481
Breast J. 2020 Sep;26(9):1688-1694
pubmed: 32875655
Genome Biol. 2011;12(4):R41
pubmed: 21527027
PLoS One. 2011 Feb 09;6(2):e16950
pubmed: 21339811
Breast Cancer Res. 2013 Nov 25;15(6):R112
pubmed: 24274653
Breast Cancer Res Treat. 2012 Nov;136(2):331-45
pubmed: 23073759
Ann Oncol. 2007 Jun;18(6):1021-9
pubmed: 17351259
Clin Cancer Res. 2009 Nov 1;15(21):6639-48
pubmed: 19825949
Mol Oncol. 2020 Mar;14(3):504-519
pubmed: 31854063
J Mol Signal. 2010 Jul 12;5:8
pubmed: 20624308
Breast Cancer Res. 2019 Feb 18;21(1):28
pubmed: 30777104
Clin Cancer Res. 2013 Sep 1;19(17):4685-96
pubmed: 23396049
PLoS One. 2015 Mar 24;10(3):e0120320
pubmed: 25803816
Genome Med. 2021 Apr 26;13(1):70
pubmed: 33902690
Oncotarget. 2017 Sep 21;8(54):92209-92226
pubmed: 29190909
Breast Cancer Res Treat. 2021 Dec;190(3):477-489
pubmed: 34542773
Clin Exp Metastasis. 2005;22(8):615-20
pubmed: 16642401
Int J Cancer. 2002 Dec 20;102(6):618-22
pubmed: 12448004
Cancers (Basel). 2022 Aug 16;14(16):
pubmed: 36010935
Breast Cancer Res. 2018 Apr 17;20(1):28
pubmed: 29665859
Breast Cancer Res Treat. 2015 Nov;154(1):155-62
pubmed: 26458824
Cell Genom. 2021 Dec 8;1(3):
pubmed: 35465400
J Immunother Cancer. 2022 Jan;10(2):
pubmed: 35140113
Oncogene. 2000 Nov 9;19(47):5413-8
pubmed: 11103943
Mol Cancer Ther. 2016 Jul;15(7):1746-56
pubmed: 27196778
Ann Oncol. 2014 Feb;25(2):358-65
pubmed: 24299959
NPJ Breast Cancer. 2021 Jun 1;7(1):72
pubmed: 34075047
Nat Rev Cancer. 2018 Aug;18(8):526
pubmed: 29748602
J Natl Cancer Inst. 2005 Jul 6;97(13):966-75
pubmed: 15998949
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3707-12
pubmed: 21317363
Sci Adv. 2022 Dec 16;8(50):eabn7983
pubmed: 36525493
CA Cancer J Clin. 2010 Nov-Dec;60(6):351-75
pubmed: 20959401
Clin Cancer Res. 2003 Sep 15;9(11):4184-9
pubmed: 14519644